Frank Attenello, MD, MS

Associate Professor of Clinical Neurological Surgery and Cancer Biology

Sloan Family Endowed Professorship in Neurological Surgery

Image of Frank Attenello, MD, MS
Is this your profile? Click to edit

Overview

Frank Attenello MD, MS is the Sloan Family Endowed Associate Professor of Neurosurgery, Biochemistry and Molecular Medicine at the Keck School of Medicine of USC, specializing in treatment of primary and metastatic brain tumors. He employs multiple surgical modalities to preserve neurologic function in tumor surgery including minimally invasive subcortical surgery (BrainPath) and laser interstitial thermal therapy. Dr. Attenello performs both cranial surgery and stereotactic radiosurgery.

Dr. Attenello received combined BS/MS degrees in Molecular Biochemistry and Biophysics from Yale University. He then received his medical degree from Johns Hopkins University School of Medicine, where he received the institutional Harvey Cushing Neurosurgery Award and the Ronald L. Bittner national Neuro-oncology research award. His work on glioblastoma and neural stem cells at Johns Hopkins was supported by a fellowship from the Howard Hughes Medical Institute. He then completed neurosurgical residency at the University of Southern California, with a postdoctoral fellowship in tumor genetics at the University of California, San Francisco.

Dr. Attenello has authored six neurosurgical book chapters and over 150 peer-reviewed manuscripts including articles in Science, BMJ, and Cancer Discovery. He was appointed Associate Scientific Advisor for Science Translational Medicine, and is an editorial board member of the Journal of Neurosurgery and the Journal of Neuroscience Research.

Dr. Attenello is also principal investigator of a basic science research laboratory studying epigenetic regulation of glioma chemoresistance as well as role of neural stem cells in brain injury (https://sites.usc.edu/attenellolab/). His laboratory is supported by a NIH K08 Research Career Development Award and several NIH and foundational grants, including generous patient support. In addition, Dr. Attenello directs a clinical outcomes laboratory studying factors associated with improved outcome in patients with neurologic disease, as well as factors driving medical trainee burnout. Using data and experience gained in the laboratory, Dr. Attenello is identifying new therapies for improved patient outcomes.

Education and Training

  • Johns Hopkins University School of Medicine, Baltimore, MD — MD — 05/2009 — Medicine
  • Yale University, New Haven, CT — BS, MS — 06/2003 — Molecular BIophysics and Biochemistry

Publications

  • Outcomes associated with ketamine administration following traumatic brain injury. J Clin Neurosci. 2026 Jun; 148:111968.. View in PubMed
  • National Trends in the Use of Flow Diversion for Management of Intracranial Aneurysms. Neurosurgery. 2026 Jan 08.. View in PubMed
  • Short-term outcomes and hospitalization cost associated with flow diversion versus coil embolization for unruptured aneurysms: A national assessment. Clin Neurol Neurosurg. 2026 01; 260:109236.. View in PubMed
  • Comorbid depression is associated with non-routine discharge following treatment of unruptured cerebral aneurysms. J Clin Neurosci. 2025 Dec; 142:111658.. View in PubMed
  • Corrigendum to Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma. J Clin Invest. 2025 08 01; 135(15).. View in PubMed
  • Hospital procedural volume is inversely linearly associated with complications in endoscopic endonasal transsphenoidal resection of pituitary tumors. J Neurosurg. 2025 Nov 01; 143(5):1377-1386.. View in PubMed
  • Trends in glioblastoma treatment, survival, and disparities in access to care in the United States from 2004 to 2019: a National Cancer Database analysis. J Neurosurg. 2025 Sep 01; 143(3):780-792.. View in PubMed
  • Multisite Benchmark Study for Standardized Relative CBV in Untreated Brain Metastases Using the DSC-MRI Consensus Acquisition Protocol. AJNR Am J Neuroradiol. 2025 03 04; 46(3):529-535.. View in PubMed
  • Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database. J Neurooncol. 2025 May; 172(3):655-665.. View in PubMed
  • The effect of temporary CSF diversion modality on shunt-dependency following aneurysmal subarachnoid hemorrhage: A nationwide assessment. J Clin Neurosci. 2025 Feb; 132:111008.. View in PubMed